Department of Anesthesiology and Critical Care, The University of Pennsylvania, Philadelphia, PA, USA.
Leonard Davis Institute for Healthcare Economics, The University of Pennsylvania, Philadelphia, PA, USA.
Sci Rep. 2021 Oct 4;11(1):19675. doi: 10.1038/s41598-021-99102-5.
Kidney function is affected in COVID-19, while kidney itself modulates the immune response. Here, hypothesize if COVID-19 urine biomarkers level can assess immune activation vs. clinical trajectory. Considering the kidney's critical role in modulating the immune response, we sought to analyze activation markers in patients with pre-existing dysfunction. This was a cross-sectional study of 68 patients. Blood and urine were collected within 48 h of hospital admission (H1), followed by 96 h (H2), seven days (H3), and up to 25 days (H4) from admission. Serum level ferritin, procalcitonin, IL-6 assessed immune activation overall, while the response to viral burden was gauged with serum level of spike protein and αspike IgM and IgG. 39 markers correlated highly between urine and blood. Age and race, and to a lesser extend gender, differentiated several urine markers. The burden of pre-existing conditions correlated with urine DCN, CAIX and PTN, but inversely with IL-5 or MCP-4. Higher urinary IL-12 and lower CAIX, CCL23, IL-15, IL-18, MCP-1, MCP-3, MUC-16, PD-L1, TNFRS12A, and TNFRS21 signified non-survivors. APACHE correlated with urine TNFRS12, PGF, CAIX, DCN, CXCL6, and EGF. Admission urine LAG-3 and IL-2 predicted death. Pre-existing kidney disease had a unique pattern of urinary inflammatory markers. Acute kidney injury was associated, and to a certain degree, predicted by IFNg, TWEAK, MMP7, and MUC-16. Remdesavir had a more profound effect on the urine biomarkers than steroids. Urinary biomarkers correlated with clinical status, kidney function, markers of the immune system activation, and probability of demise in COVID-19.
肾功能在 COVID-19 中受到影响,而肾脏本身调节免疫反应。在这里,假设 COVID-19 尿液生物标志物水平能否评估免疫激活与临床轨迹。考虑到肾脏在调节免疫反应方面的关键作用,我们试图分析预先存在功能障碍患者的激活标志物。这是一项 68 例患者的横断面研究。在入院后 48 小时(H1)内采集血液和尿液,随后在入院后 96 小时(H2)、7 天(H3)和最多 25 天(H4)采集。血清铁蛋白、降钙素原和 IL-6 评估整体免疫激活,而血清刺突蛋白和α刺突 IgM 和 IgG 水平则用于评估病毒载量的反应。39 个标志物在尿液和血液之间高度相关。年龄、种族,在较小程度上还有性别,区分了几个尿液标志物。预先存在疾病的负担与尿液 DCN、CAIX 和 PTN 相关,但与 IL-5 或 MCP-4 呈负相关。更高的尿液 IL-12 和更低的 CAIX、CCL23、IL-15、IL-18、MCP-1、MCP-3、MUC-16、PD-L1、TNFRS12A 和 TNFRS21 表明为非幸存者。APACHE 与尿液 TNFRS12、PGF、CAIX、DCN、CXCL6 和 EGF 相关。入院时尿液 LAG-3 和 IL-2 预测死亡。预先存在的肾脏疾病具有独特的尿液炎症标志物模式。急性肾损伤与 IFNg、TWEAK、MMP7 和 MUC-16 相关,在一定程度上可以预测。瑞德西韦对尿液生物标志物的影响比类固醇更明显。尿液生物标志物与 COVID-19 中的临床状态、肾功能、免疫系统激活标志物和死亡概率相关。